Xencor Inc. (XNCR)
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed. XNCR's lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally.
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago.
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.07 per share a year ago.
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Upgraded to Buy: Here's Why
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.
